Announces that Chairman and CEO James A.

Aethlon to introduce new adaptive dialysis-like affinity platform technology at C21 partnering conference Aethlon Medical, Inc. , the pioneer in developing therapeutic filtration devices to handle infectious malignancy and disease, announces that Chairman and CEO James A.m. Pacific time at the Meritage Resort in Napa, Calif. Joyce.Siegfried and Beebe say the next step is to extend their studies of patients and to explore the consequences of elevated oxygen amounts in animal models of glaucoma. They also plan to measure oxygen utilization in sufferers by placing a modified contact lens on the attention to measure just how much oxygen has been consumed. ‘It’s not that older patients or African-American individuals are somehow getting more oxygen into their eye,’ Siegfried explains. ‘Rather, aging may bring about lower oxygen consumption, leaving higher amounts in the eye. In contrast African-Americans may have significantly more efficient oxygen metabolism, with the same result. The surplus oxygen might result in the formation of oxygen byproducts that cause cellular damage. However, more research is required. Whenever we understand the underlying reason for elevated oxygen and how it could damage the eye, we shall be in a better position to build up ways to prevent this disease.